Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immunology

Set Alert for Immunology

AstraZeneca To Challenge GSK After Clinching Lupus Drug Approval

Fears that US regulators would take issue with AstraZeneca's decision to change the endpoints of a second pivotal trial for anifrolumab were unfounded and the first-in-class type I interferon inhibitor is the first new treatment for systemic lupus erythematosus in more than 10 years.

Approvals Immune Disorders

UCB And Analysts Believe Bimekizumab Will Be Super-Blockbuster

The psoriasis market is a tough one for bimekizumab to crack but UCB head of immunology Emmanuel Caeymaex believes the clinical package and investment in promotion will see the IL-17A and IL-17F inhibitor topple its rivals.

Launches Sales & Earnings

Sanofi’s Dupixent Benefits In Chronic Spontaneous Urticaria Add To Strong Second Quarter

Sanofi’s sales grew strongly in the second quarter, driven by the immunologic Dupixent and its vaccines business, with the company also reporting success in a further potential indication for the product, chronic spontaneous urticaria. The big pharma has raised its EPS guidance for the year.

Sales & Earnings Inflammation

Seres Plans Deep Dive After Microbiome Drug Fails In Ulcerative Colitis Trial

The company plans an intensive review to determine the path forward for SER-287. A similar deep dive led to the successful revival of its C. difficile drug, SER-109, which it plans to submit for approval.

Clinical Trials Research and Development Strategies

Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing

Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.

Sales & Earnings Business Strategies

Galapagos Pledges More Restraint On Pipeline Potential

The Belgium-headquartered firm has struggled of late to impress investors, most recently with data from its salt-inducible kinase inhibitors, and CMO Walid Abi-Saab told Scrip that one reason could be "the level of optimism that prevails in the company. We jump on things a bit ahead of time."

Clinical Trials Business Strategies

Swedish Biotech Developing Stem Cell Therapies From Amniotic Fluid

Swedish biotech Amniotics is developing a broad pipeline of unique stem cell therapeutics based on technology that is broadly applicable to major disease markets which should eventually draw the attention of big pharma players, its CEO tells Scrip.

Clinical Trials StartUps and SMEs

Toledo Data Fail To Give Galapagos A Lift

Lead Toledo compound GLPG3970 has failed to live up to expectations in three clinical studies, setting Galapagos's pipeline plans back and causing further concern among the investment community.

Clinical Trials Immune Disorders

Small Swedish Biotech Cyxone’s US CEO Has ‘Big Plans’

Swedish biotech Cyxone’s CEO tells Scrip about its aims to become a cutting-edge developer of disease-modifying treatments for rheumatoid arthritis and multiple sclerosis, but says the Scandinavian industry needs a ‘mindset change’.

Clinical Trials Commercial

Sosei Heptares Turns To AI In GPCR-Focused Drug Discovery Pact

Sosei Heptares hopes to create transformative therapeutics for immune diseases by combining its GPCR structure-based drug design and early development capabilities with InveniAI's already validated AI-based platform, its head of new target identification tells Scrip.

Companies Deals

10 US Approval Decisions To Look Out For In Q3

This quarter has already seen a complete response letter for Iterum Therapeutics’ antibiotic sulopenem but a raft of other products are expecting approval decisions from the US Food and Drug Administration in the next three months. With the help of analysts at Biomedtracker, Scrip takes a look at 10 of the more interesting ones.

Approvals Companies

Rinvoq Shows Strong UC Efficacy, But Will JAK Ghosts Haunt It?

Safety appears balanced between the drug and placebo arms in upadacitinib’s third Phase III trial in ulcerative colitis, but there were low numbers of MACE and there are lingering safety concerns about the JAK class overall.

FDA Inflammation
See All
UsernamePublicRestriction

Register